KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Gross Profit: 2014-2024

Historic Gross Profit for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$181,000.

  • Palvella Therapeutics' Gross Profit fell 113.93% to -$181,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $951,000, marking a year-over-year decrease of 97.78%. This contributed to the annual value of -$430,000 for FY2024, which is 101.00% down from last year.
  • Per Palvella Therapeutics' latest filing, its Gross Profit stood at -$181,000 for Q4 2024, which was up 17.73% from -$220,000 recorded in Q3 2024.
  • Over the past 5 years, Palvella Therapeutics' Gross Profit peaked at $20.1 million during Q2 2023, and registered a low of -$220,000 during Q3 2024.
  • For the 3-year period, Palvella Therapeutics' Gross Profit averaged around $6.2 million, with its median value being $3.7 million (2022).
  • Its Gross Profit has fluctuated over the past 5 years, first spiked by 443.16% in 2023, then tumbled by 113.93% in 2024.
  • Over the past 5 years, Palvella Therapeutics' Gross Profit (Quarterly) stood at $1.9 million in 2020, then spiked by 349.81% to $8.4 million in 2021, then plummeted by 30.76% to $5.8 million in 2022, then crashed by 77.78% to $1.3 million in 2023, then slumped by 113.93% to -$181,000 in 2024.
  • Its last three reported values are -$181,000 in Q4 2024, -$220,000 for Q3 2024, and $53,000 during Q1 2024.